FDA shares eased manufacturing rules for cell and gene therapiesnews2026-01-12T18:04:55+00:00January 12th, 2026|Endpoints News|
FDA lifts partial hold on Merck, Daiichi’s Phase 3 lung cancer studynews2026-01-12T17:47:28+00:00January 12th, 2026|Endpoints News|
Walmart makes tepid return to healthcarenews2026-01-12T17:43:40+00:00January 12th, 2026|Endpoints News|
Eisai licenses Nuvation lung cancer pill; Alnylam’s stock dips after sales data reportnews2026-01-12T16:22:25+00:00January 12th, 2026|Endpoints News|
AbbVie jumps into PD-1xVEGF bispecific race, pays $650M upfront to RemeGennews2026-01-12T15:41:14+00:00January 12th, 2026|Endpoints News|
Eli Lilly, Nvidia sign five-year, up to $1B deal for AI laboratorynews2026-01-12T15:00:19+00:00January 12th, 2026|Endpoints News|
FDA again rejects Atara, Pierre Fabre’s cell therapy for Epstein-Barr virusnews2026-01-12T13:59:22+00:00January 12th, 2026|Endpoints News|
Arkin Capital raises $100M to back a dozen early-stage biotechsnews2026-01-12T13:00:45+00:00January 12th, 2026|Endpoints News|
#JPM26: Moderna CEO Bancel talks deals, flu and RSV strategynews2026-01-12T12:00:35+00:00January 12th, 2026|Endpoints News|
#JPM26: Day 1 at the JP Morgan Healthcare Conferencenews2026-01-12T12:00:14+00:00January 12th, 2026|Endpoints News|
